The Francis Crick Institute
1-s2.0-S022352342200006X-main.pdf (3.01 MB)

A new strategy for hit generation: Novel in cellulo active inhibitors of CYP121A1 from Mycobacterium tuberculosis via a combined X-ray crystallographic and phenotypic screening approach (XP screen)

Download (3.01 MB)
journal contribution
posted on 2022-07-27, 13:36 authored by M Frederickson, IR Selvam, D Evangelopoulos, KJ McLean, MM Katariya, RB Tunnicliffe, B Campbell, ME Kavanagh, S Charoensutthivarakul, RT Blankley, CW Levy, LPS de Carvalho, D Leys, AW Munro, AG Coyne, C Abell
There is a pressing need for new drugs against tuberculosis (TB) to combat the growing resistance to current antituberculars. Herein a novel strategy is described for hit generation against promising TB targets involving X-ray crystallographic screening in combination with phenotypic screening. This combined approach (XP Screen) affords both a validation of target engagement as well as determination of in cellulo activity. The utility of this method is illustrated by way of an XP Screen against CYP121A1, a cytochrome P450 enzyme from Mycobacterium tuberculosis (Mtb) championed as a validated drug discovery target. A focused screening set was synthesized and tested by such means, with several members of the set showing promising activity against Mtb strain H37Rv. One compound was observed as an X-ray hit against CYP121A1 and showed improved activity against Mtb strain H37Rv under multiple assay conditions (pan-assay activity). Data obtained during X-ray crystallographic screening were utilized in a structure-based campaign to design a limited number of analogues (less than twenty), many of which also showed pan-assay activity against Mtb strain H37Rv. These included the benzo[b][1,4]oxazine derivative (MIC90 6.25 μM), a novel hit compound suitable as a starting point for a more involved hit to lead candidate medicinal chemistry campaign.


Crick (Grant ID: 10060, Grant title: Carvalho FC001060)